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Abstract
BACKGROUND: Pancreatic cancer is among themost dismal of humanmalignancies. The 5-year survival rate is lower
than 5%. The identification of precursor lesions would be the main step to improve this fatal outcome. One precursor
lesions are called pancreatic intraepithelial neoplasia (PanIN) and are graduated in grade 1 to 3, whereas grade 3 is
classified as carcinoma in situ. Currently, no reliable, noninvasive imaging technique (e.g., ultrasound, computed to-
mography, magnet resonance imaging) exists to verify PanINs. METHODS: Recently, a transgenic mouse model of
pancreatic cancer was established in which the tumor progression of human pancreatic carcinoma is reproduced.
These so-called Pdx-1−Cre; LSL-KrasG12D/+; LSL-Trp53R172H/+mice develop PanINs, which transform to invasive
growing pancreatic carcinoma. The pancreata of mice of different ages were immunohistochemically stained using
α-GLUT-2 antibodies. Furthermore, mice underwent positron emission tomography (PET)–computed tomography
(CT) with 18F-fluorodeoxyglucose (FDG) to evaluate early detection of PanIN lesions. RESULTS: An expression of
GLUT-2 in murine PanINs was found in PanINs of grade 1B and higher. This finding is associated with an elevated
glucose metabolism, leading to the detection of precursor lesions of pancreatic cancer in the FDG PET-CT scan. In
addition, immunohistochemical staining of GLUT-2was detectable in 45 (75%) of 60 human PanINs,whereas PanINs
of grade 1B and higher showed a very extensive expression. CONCLUSIONS: In conclusion, we demonstrate for the
first time that an elevated glucose metabolism occurs already in precursor lesions of murine and human pancreatic
carcinoma. These findings are the basis for the detectionof precursor lesions byPET-CT, thereby helping improving the
prognosis of this devastating disease.
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Introduction
Pancreatic cancer is a devastating and almost uniformly lethalmalignancy
that accounts for approximately 33,000 deaths in the United States every
year, rendering it the fourth most common cause of cancer-related mor-
tality [1]. Although the past decades have seen intense research efforts
aimed at a better understanding of the underlying etiologic and patho-
physiological mechanisms, this increased knowledge could not so far
be translated successfully into better clinical treatment strategies and
improved patient survival. In fact, during the past 30 years, the overall
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median 5-year survival rates for pancreatic cancer have improved only
marginally and are currently around 5% [1,2]. Notably, there is now
strong evidence that invasive pancreatic adenocarcinoma proceeds
through a morphologic spectrum of noninvasive ductal lesions such
as pancreatic intraepithelial neoplasia (PanIN) and that histologic pro-
gression of these lesions toward invasive cancer is associated with
the progressive accumulation of genetic abnormalities [2,3]. The analyses
of pancreatic carcinoma have unfortunately been hampered by a number
of unique challenges. For instance, at the time of diagnosis, pancreatic
cancer is usually at an advanced stage and has often metastasized. The
detection of these noninvasive precursor lesions would help to improve
the diagnosis fundamentally. The preclinical study of PanINs has recently
been made possible by the generation of genetically modified animal
models, which recapitulate human PanINs and invasive pancreatic can-
cer on a genetic and histomorphologic level [4,5]. Now, for the first
time, early detection studies or chemopreventive studies are possible [6].
In the postprandial state, increased plasma levels of glucose as well
as other nutrients stimulate pancreatic β cells to secrete insulin. The
initiating event in this process is the cellular uptake of glucose through
the cell surface facilitative glucose transporter protein (GLUT) 2 that
functions to transport glucose in proportion to circulating levels.
GLUT2, also known as solute carrier family 2 (facilitated glucose trans-
porter) member 2 (SLC2A2), is a transmembrane carrier protein that
enables passive glucosemovement across cell membranes and is expressed
in the intestine, pancreas, kidney, and liver, which all play key roles in the
handling of dietary sugars [7]. Positron emission tomography (PET)with
18F-fluorodeoxyglucose (FDG) has been widely used in recent years for
the diagnosis and staging of pancreatic ductal adenocarcinoma (PDAC)
[8]. Indeed, FDGPET is regarded to bemore accurate in the detection of
primary tumors and identification of metastases than other imaging
methods [9].Despite an increasing interest in the development of specific
probes for the detection of preneoplastic lesions and tumors, FDG is the
most commonly applied PETstrategy. The use of FDG for cancer detec-
tion relies on the increased glucose uptake associatedwith the exacerbated
glycolytic metabolism of most malignant cells [10]. Accelerated glucose
consumption can be the consequence of a variety of factors, including the
overexpression of glucose transporters and hexokinases [11,12]. Recent
developments using a combination of PET and computed tomography
(FDG-PET-CT) have demonstrated further improvements in diagnostic
sensitivity ranging from 89% to 100%. Very recently, Abasolo et al. [13]
evaluated FDG PET imaging in Ela1-myc mice, a pancreatic cancer
mouse model resulting in the development of tumors with either acinar
or mixed acinar-ductal phenotype. They found that mixed acinar-ductal
tumors could be identified several weeks before they could be palpated:
Because the Ela1-myc model does not recapitulate the progression of
PanIN associated with human PDAC, it was not possible to establish
when—during the progression of intraductal lesions—Glut2 overexpres-
sion took place.
In this study, we show for the first time that GLUT-2 expression
is detectable during an early stage of murine and human precursor
lesions of pancreatic cancer. Furthermore, we demonstrate that these
lesions are detectable by PET-CT in a genetically engineered mouse
model of pancreatic cancer.
Materials and Methods
Mice
Conditional LsL-Trp53R172H [14], LsL-KrasG12D, and Pdx1-Cre [4]
strains were interbred to obtain LsL-KrasG12D;Pdx1-Cre double mutant
animals or LsL-KrasG12D;LsL-Trp53R172H;Pdx1-Cre triple mutant ani-
mals on a mixed 129/SvJae/C57BL/6 background as previously de-
scribed [5]. All mice were generated from the same initial stock. All
experiments were approved by the local committees for animal care
and use. Animals were maintained in a climate-controlled room kept
at 22°C, exposed to a 12:12-hour light-dark cycle, fed standard labora-
tory chow, and given water ad libitum.
Genotyping
For genotyping, genomic DNAwas extracted from tail cuttings using
the REDExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich, St Louis,
MO). Three polymerase chain reactions were carried out for each
animal to test for the presence of the oncogenic Kras (using LoxP
primers), p53, and Pdx1-Cre transgene constructs (using Cre-specific
primers along with Gabra as a positive control), respectively.
Tissue Microarrays
Tissue samples were obtained from the pathology archives of the
Johns Hopkins Medical Institutions (Baltimore, MD). PanIN tissue
microarray blocks were also created as described previously [15]. In
short, 60 PanIN lesions were selected from 33 patients with pancreatic
ductal adenocarcinoma. PanIN lesions were separated into PanIN-1,
PanIN-2, or PanIN-3 grades either at the time of microarray creation
or after a review by A.M.
Histologic Evaluation
After completion of the study, mice were killed, and the pancreas
was removed and inspected for grossly visible tumors and preserved
in 10% formalin solution (Sigma-Aldrich) for histology. Formalin-fixed
paraffin-embedded tissues were sectioned (4 μm) and stained with
hematoxylin and eosin. Six sections (100 μm apart) of pancreatic tis-
sues were histologically evaluated by an experienced gastrointestinal
pathologist (A.M.). Mouse PanIN (mPanINs) lesions were classified ac-
cording to histopathologic criteria as recommended elsewhere [16,17].
Immunostaining
For immunolabeling, formalin-fixed and paraffin-embedded ar-
chived tumor samples and corresponding normal tissues were stained
as previously described [18]. Concentrations and sources of primary
antibodies are available on request. Briefly, slides were heated to
60°C for 1 hour, deparaffinized using xylene, and hydrated by a graded
series of ethanol washes. Antigen retrieval was accomplished by micro-
wave heating in 10 mM sodium citrate buffer, pH 6.0, for 10 min-
utes. For immunohistochemistry, endogenous peroxidase activity was
quenched by 10 minutes of incubation in 3% H2O2. Nonspecific
binding was blocked with 10% serum. Sections were then incubated
with primary antibodies overnight at 4°C. For immunohistochemistry,
bound antibodies were detected using the avidin-biotin complex perox-
idase method (ABC Elite Kit; Vector Labs, Burlingame, CA). Final
staining was developed with the Sigma FASTDAB peroxidase substrate
kit (Sigma, Deisenhofen, Germany).
FDG-PET-CT In Vivo
A Siemens Inveon small-animal multimodality PET-CTsystem (Pre-
clinical Solutions, Siemens Healthcare Molecular Imaging, Knoxville,
TN) was used for data acquisition. This PET-CT system is character-
ized by the combination of two independently operating PET and CT
scanner. The PET module has an effective transaxial field of view
(FOV) of approximately 10 cm and an axial FOVof 12.7 cm, whereas
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radial, tangential, and axial resolution at the center of FOV is better
than 1.5 mm. PET acquisitions were carried out with default settings
of coincidence timing window of 3.4 nanoseconds and energy win-
dow of 350 to 650 keV. Images were reconstructed using 3D Ordered
Subset-Expectation Maximization (OSEM-3D, 2 iterations, 16 sub-
sets) algorithm followed by maximum a posteriori algorithm (18 itera-
tions, 16 subsets, beta smoothing factor 0.1) (Siemens, Germany). Pixel
size was 0.431 mm and slice thickness is 0.796 mm based on the size of
the image matrix of 256 × 256 × 159. Attenuation was corrected based
on the CT measurements. The CT module consists of a cone beam
micro x-ray source (50-μm focal spot size) and a 2048 × 3072 pixel
x-ray detector. Maximum FOV of the detector is 5.5 cm × 8.4 cm.
Our standard micro-CT imaging protocol used 80 kV at 500 μA,
360 degrees of rotation, and 200 projections per bed position. Two
bed positions were acquired with an overlap of 43.6%. Exposure time
of each projection was 300 milliseconds. Micro-CT images were re-
constructed using Shepp-Logan filter and cone beam–filtered back-
projection (Modified Feldkamp algorithm) into 256 × 256 × 601 CT
data sets with 0.217-mm voxel dimensions. Acquisitions and re-
constructions were carried out using Siemens Acquisition workplace
(IAW) software version 1.4.3 (Siemens).
After the CTscan was complete, the mouse bed was translated axially
and centered within the PETmodule. The PET data were acquired 40
to 60 minutes after injection of FDG. Because the mouse remains in
the same position on the bed for both CTand PETacquisitions and the
relative positions of the field of views of PET and CT are known, the
CT data were transformed to fuse and coregister the PETand CT data.
Visualization and analysis of the coregistered PET-CT data were per-
formed with the Siemens Inveon Research Workplace (IRW) software
version 2.2 (Siemens).
In preparation for PET-CT, mice were anesthetized with 1.5% to
2% vaporized isoflurane (DeltaSelect, Dreieich, Germany) in oxygen
(1.5 l/min) to prevent animal movement and reduce imaging arti-
facts. During anesthesia, respiratory frequency was continuously moni-
tored. Hypothermia was prevented by placing the mice on heating pads
(36°C). 18F (half-life, 109 minutes) labeled FDG (Eckert & Ziegler,
Bad Berka, Germany) with an activity of 9.6 ± 0.5 MBq was injected
intravenously into the lateral tail vein of anesthetized mice in a volume
of 90 to 110 μl of 0.9% NaCl. Because extended fasting times may
profoundly affect outcome of experimental disease in small rodents
with approximately 20- to 25-g body weight and high metabolic activ-
ity, fasting was completely omitted, and mice had free access to water
and food right before FDG administration and imaging.
Results
Development of PanINs in LsL-KrasG12D;Pdx1-Cre and of
Pancreatic Cancer in LsL-KrasG12D;LsL-Trp53R172H;
Pdx1-Cre Mice
As previously described in the initial reports [4,5], we observed
development of low-grade (Figure 1A) and high-grade (Figure 1B)
PanINs in LsL-KrasG12D;Pdx1-Cre and fully invasive pancreatic cancers
(Figure 1C ) in LsL-KrasG12D;LsL-Trp53R172H;Pdx1-Cre transgenic
mice. The histologic diagnosis resembled ductal adenocarcinomas of
the pancreas or its precursor lesions observed in humans.
Expression of Glut-2 in LsL-KrasG12D;LsL-Trp53R172H;
Pdx1-Cre–Derived Murine Precursor Lesions and
Pancreatic Cancer
The pancreas was harvested from LsL-KrasG12D;Pdx1-Cre and LsL-
KrasG12D;LsL-Trp53R172H;Pdx1-Cre transgenic mice and stained for
Glut-2 expression using immunohistochemistry.
In neoplastic mouse tissue, Glut-2 was expressed in 85% of all
PanIN lesions graded 1B or higher (Figure 2, A and B). Whereas PanIN
1A epithelium did not show Glut-2 expression (Figure 2A, arrows),
higher-graded PanIN lesions had a strong Glut-2 expression. Glut-2
expression was restricted to tumor cells, whereas the stromal compart-
ment of the carcinoma did not show any GLUT-2 expression. These
findings suggest that elevated glucose metabolism is an early event in
PanIN progression and may help detect precursor lesions during a non-
invasive stage. Furthermore, we found expression of Glut-2 in invasive
pancreatic carcinoma (Figure 2B). In wild-type mice, Glut-2 expression
was detected in islet cells only (Figure 2E).
Expression of Glut-2 in Human Precursor Lesions of
Pancreatic Cancer
After the evidence of GLUT-2 expression inmurine precursor lesions
of pancreatic cancer at stages as early as PanIN 1B, we next sought
to translate our findings into the clinics. Therefore, we evaluated a panel
Figure 1. (A) Low-grade mPanIN lesion (mPanIN-1A) in a LsL-KrasG12D; Pdx1-Cre mouse. (B) High-grade PanIN lesion after 5 months in a
LsL-KrasG12D;LsL-Trp53R172H;Pdx1-Cremouse. (C) Invasive poorly differentiated ductal adenocarcinoma from a 5-month-old LsL-KrasG12D;
LsL-Trp53R172H;Pdx1-Cre mouse.
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of human PanINs by tissue microarray by GLUT-2 immunohisto-
chemistry. Remarkably, we found the same expression pattern as
in the murine counterparts. GLUT-2 expression was detectable in
45 (75%) of 60 human PanIN lesions graded 1B or higher (Figure 2,
C and D). Interestingly, Glut-2 expression was also observed only in
tumor but not in stromal cells (Figure 2, C and D).
Invasive Ductal Carcinomas Show High FDG Uptake
in PET-CT
To determine whether FDG PET-CT could detect invasive carci-
noma of LsL-KrasG12D;LsL- Trp53R172H;Pdx1-Cremice, we first studied
four 5-month-old transgenic mice bearing palpable tumors and age-
matched nontransgenic littermates. All four control wt mice failed to
display an abnormal abdominal FDG uptake in the pancreatic region
(Figure 3, A and D). As expected, no tumor could be found in the
pancreas of wt mice (Figure 3G ). On the contrary, all transgenic litter-
mates showed a strong FDG uptake in the pancreatic area (Figure 3C),
correlating with a huge tumor burden in PET-CT scan (Figure 3F )
and confirmed macroscopically in the abdomen of the transgenic mice
(Figure 3I ).
Precursor Lesions of Pancreatic Cancer Show FDG Uptake
in PET-CT
After proving the detection and visualization of invasive pancreatic
carcinoma in the LsL- KrasG12D;LsL-Trp53R172H;Pdx1-Cre mice, we
next evaluated if it would be possible also to visualize precursor lesions
of pancreatic cancer. Therefore, we analyzed four LsL-KrasG12D;Pdx1-
Cremice, which do not develop invasive pancreatic carcinoma but only
PanIN lesions [4,5]. Again, we studied 5-month-old transgenic mice
and age-matched nontransgenic littermates, and we were able to find
a weak but clear visible signal in the pancreatic area (Figure 3, B and
E ). After laparotomy, no tumor was palpable or visible macroscopi-
cally (Figure 3H ). To underline our findings, we show a series of
acquired images of PET-CT in a wild-type (Figure 4A) and a LsL-
KrasG12D;Pdx1-Cre mouse (Figure 4B), demonstrating that the signal
was detectable throughout the series of images. According to our
immunohistochemistry results, where Glut-2 expression was found
only in tumor but not stromal cells, these signals arise from PanIN
lesions and not from surrounding stroma or extracellular tissue.
Discussion
PET uses radiolabeled FDG, a glucose analog, to detect enhanced
metabolism of glucose by malignant cells causing selective uptake of
the radiotracer. FDG enters the cell through the glucose transporter
protein (GLUT) transporter system and accumulates there because it
is not completely metabolized. In normal pancreatic tissue, one of these
transporters, GLUT2, is expressed only in pancreatic β cells [7]. PET
has demonstrated efficacy in the evaluation of metastatic disease in dif-
ferent types cancer, such as pancreatic cancer [19]. Overall sensitivity of
PET scan alone for pancreatic adenocarcinoma has been reported as
85% to 96% [20]. Although useful, the lack of anatomic localization
limited the overall utility of the test. More recently, with improved
computing abilities and technology, PET has been fused with CT to
add precision anatomic and functional localization [20]. This colocali-
zation has the potential benefit of improving diagnosis, staging, treat-
ment planning, and evaluation of response to treatment in patients with
pancreatic cancer. PET-CT could improve diagnosis by detection of
the primary cancer. In addition, PET-CT could improve staging by
identifying local regional disease and occult metastatic disease and
Figure 2. (A) GLUT-2 was expressed in virtually all murine PanIN lesions graded 1B or higher. PanIN 1A epithelium did not show GLUT-2
expression (arrows), and higher-graded PanIN lesions had a strong GLUT-2 expression (arrowheads). (B) GLUT-2 in invasive pancreatic
carcinoma. (C, D) GLUT-2 expression was detectable in human PanIN 1B lesions (C and D). Interestingly, GLUT-2 expression was also
observed only in the tumor and not in the stromal cells. (E) Normal GLUT-2 expression in islet cells.
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confirming suspicious metastatic lesions found on standard CT. Con-
cerning the usefulness of FDG-PET in early stage pancreatic neoplasia,
encouraging results have recently been reported in the diagnosis of
intraductal papillary mucinous neoplasms of the pancreas with better
sensitivity than conventional imaging [21].
In our study, we now show for the first time that GLUT-2 is
expressed in precursor lesions of pancreatic cancer at an early non-
invasive stage, making it a possible target for early detection of pan-
creatic cancer. This would be especially important for patients with
familial pancreatic cancer that accounts for 3% to 5% of all pan-
creatic cancer cases [22]. Using immunohistochemistry, we found
strong expression of GLUT-2 in murine PanINs grade 1B in a gen-
etically engineered mouse model of pancreatic cancer but also in
human PanINs using a tissue microarray. This shows at which stage
in tumor progression of pancreatic cancer change in glucose metab-
olism seems to be detectable. Our results close a gap left behind by
a recently published study by Abasolo et al. [13]. Using Ela1-myc
mice, they showed that mixed acinar-ductal tumors could be iden-
tified by FDG PET several weeks before they could be detected by
hand palpation. To gain insight into the biologic basis of the differ-
ential FDG uptake, glucose transporter expression was studied in
microdissected tumor areas enriched for acinar or ductal cells. They
found that GLUT2 messenger RNA levels were up to 20-fold higher
in ductal than in acinar tumors. Besides, GLUT2 protein overexpres-
sion was found in ductal neoplastic cells but not in the surrounding
stroma. Because the Ela1-myc model does not recapitulate the pro-
gression of PanIN progression model associated with human PDAC,
it was not possible for the authors to establish when—during the pro-
gression of intraductal lesions— GLUT2 overexpression takes place.
The authors stated that their work did not have direct implications
regarding the early detection of pancreatic cancer in humans. How-
ever, their findings support the notion that the study of the FDG
PET imaging properties of pancreatic ductal precursor lesions may
contribute to develop better imaging methods to detect preneoplastic
Figure 3. (A–C) PET scans. (D–F) Overlay of PET scan and CT acquired simultaneously. (E–I) Macroscopical evaluation of the pancreas
and abdominal region. Pictures in one column were generated from an individual mouse. (A, D) Control wt mice displaying normal
abdominal FDG uptake without enrichment in the pancreatic region (circle in A). As expected, no tumor could be found in the pancreas
of the wt mice (circle in G). (B, E) LsL-KrasG12D;Pdx1-Cre mice demonstrated a weak but clear visible signal in the pancreatic area (circle
in B). After laparotomy, no tumor was palpable or visible macroscopically (circle in H). (C, F) All LsL-KrasG12D;LsL-Trp53R172H;Pdx1-Cre
littermates showed a strong FDG uptake in the pancreatic area (circle in C), which correlates to a huge tumor burden in PET-CT scan (F).
As shown in I, a huge invasive pancreatic cancer was found in the abdomen of the transgenic mice (circle in I).
184 GLUT-2 in PanINs Fendrich et al. Neoplasia Vol. 13, No. 2, 2011
lesions [13]. The conditional LsL-KrasG12D;Pdx1-Cre mice [4] used
in our study is considered a very valuable tool to study PanIN biology
because it mimics rather a slow progression from PanIN 1 over PanIN 2
and 3 lesions to invasive cancer in around 12 to 15 months. Further-
more, LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre [5] mice
manifest widely metastatic pancreatic ductal adenocarcinoma that
recapitulates the human spectrum. The use of these models now pro-
vides the opportunity to conduct chemopreventive studies on pan-
creatic cancer.
After we found an impressive GLUT-2 expression in 85% of mu-
rine PanINs graded 1B or higher, we stained more than 60 human
PanINs from a tissue microarray for GLUT-2 and found similar
expression pattern. Of 60 human PanINs, 45 (75%) revealed ex-
pression of GLUT-2, and virtually all PanINs graded 1B or higher
were GLUT-2–positive. As mentioned in the study of Abasolo et al.
[13], the expression was restricted to tumor cells but not to the sur-
rounding stromal compartment.
The next step of in study was to evaluate LsL-KrasG12D;Pdx1-Cre
mice, which do not develop invasive pancreatic carcinoma but de-
velop PanIN lesions [4,5]. We studied 5-month-old transgenic mice
and age-matched nontransgenic littermates and were able to find a
weak but clear visible signal in the pancreatic area, whereas in wild-
type mice, no such signal was detectable. Because GLUT-2 expres-
sion was restricted to neoplastic but not stromal cells, this signal is
most likely based on real glucose uptake in PanIN lesions. Because
only PanIN 3 are classified as carcinoma in situ, detecting noninva-
sive PanIN stages in PET-CTwould have a major effect on improving
the prognosis of this fatal disease and would help to detect pre-
cursor lesions in patients with familial pancreatic history in a curable
stage [22]. Furthermore, we found a strong FDG uptake in the
pancreatic area in LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre
mice, which correlates to a huge tumor burden in the PET-CT
scan, and this was verified macroscopically in the abdomen of the
transgenic mice.
In conclusion, we demonstrate for the first time that an elevated
glucose metabolism occurs already in precursor lesions of murine
and human pancreatic carcinoma. These findings are the basis for
the detection of precursor lesions by PET-CT, thereby helping improv-
ing the prognosis of this devastating disease.
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